4.13
-0.22 (-5.06%)
| Penutupan Terdahulu | 4.35 |
| Buka | 4.36 |
| Jumlah Dagangan | 815,361 |
| Purata Dagangan (3B) | 901,811 |
| Modal Pasaran | 511,612,480 |
| Harga / Jualan (P/S) | 6.36 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -197.64% |
| Margin Operasi (TTM) | -123.58% |
| EPS Cair (TTM) | -1.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.60% |
| Nisbah Semasa (MRQ) | 4.46 |
| Aliran Tunai Operasi (OCF TTM) | -136.07 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.34 M |
| Pulangan Atas Aset (ROA TTM) | -27.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | ADC Therapeutics SA | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.88 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.58% |
| % Dimiliki oleh Institusi | 66.89% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Redmile Group, Llc | 31 Dec 2025 | 15,666,731 |
| Tcg Crossover Management, Llc | 31 Dec 2025 | 11,390,175 |
| Prosight Management, Lp | 31 Dec 2025 | 8,477,338 |
| Orbimed Advisors Llc | 31 Dec 2025 | 5,822,854 |
| Eventide Asset Management, Llc | 31 Dec 2025 | 3,364,067 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 30 Jan 2026 | Pengumuman | $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium |
| 08 Jan 2026 | Pengumuman | ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates |
| 08 Jan 2026 | Pengumuman | ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 02 Jan 2026 | Pengumuman | ADC Therapeutics Announces New Employee Inducement Grant |
| 19 Dec 2025 | Pengumuman | Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |